Our Terms of Service and Privacy Policy have changed.
By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.
By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.
| 11.46 Delayed Data As of 10:17am ET |  +0.07 / +0.61%Today’s Change | 7.86 Today|||52-Week Range 18.85 | -22.78% Year-to-Date |
| Momenta to Regain Rights to Humira Biosimilar from Shire Sep 28 / Zacks.com - Paid Partner Content |
| Previous close | 11.39 |
| Today’s open | 11.41 |
| Day’s range | 11.30 - 11.53 |
| Volume | 38,122 |
| Average volume (3 months) | 537,624 |
| Market cap | $808.5M |
| Dividend yield | -- |
| Earnings growth (last year) | +30.89% |
| Earnings growth (this year) | +8.56% |
| Earnings growth (next 5 years) | -- |
| Revenue growth (last year) | +71.58% |
| P/E ratio | NM |
| Price/Sales | 10.45 |
| Price/Book | 2.12 |
| Today’s change | Today’s % change | |
|---|---|---|
| RTRXRetrophin Inc | +0.06 | +0.27% |
| AMAGAMAG Pharmaceuticals... | 0.00 | 0.00% |
| BPMCBlueprint Medicines ... | +0.61 | +2.17% |
| ANIPANI Pharmaceuticals ... | +0.28 | +0.42% |
| Next reporting date | November 2, 2016 |
| EPS forecast (this quarter) | -$0.29 |
| Annual revenue (last year) | $89.7M |
| Annual profit (last year) | -$83.3M |
| Net profit margin | -92.93% |
Sector Health Technology |
Industry Biotechnology |
President, CEO & Class II Director Craig A. Wheeler |
Chief Operating Officer Matthew P. Ottmer |
Corporate headquarters Cambridge, Massachusetts |
